PT1904102E - Anticorpos anti-receptor ccr7 para o tratamento do cancro - Google Patents

Anticorpos anti-receptor ccr7 para o tratamento do cancro Download PDF

Info

Publication number
PT1904102E
PT1904102E PT06776128T PT06776128T PT1904102E PT 1904102 E PT1904102 E PT 1904102E PT 06776128 T PT06776128 T PT 06776128T PT 06776128 T PT06776128 T PT 06776128T PT 1904102 E PT1904102 E PT 1904102E
Authority
PT
Portugal
Prior art keywords
cells
ccr7
antibody
antibodies
cell
Prior art date
Application number
PT06776128T
Other languages
English (en)
Portuguese (pt)
Inventor
Cecilia Munoz Calleja
Manuel Jesus Alfonso Perez
Sonia Lopez Giral
Original Assignee
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Autonoma filed Critical Univ Madrid Autonoma
Publication of PT1904102E publication Critical patent/PT1904102E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT06776128T 2005-07-06 2006-07-05 Anticorpos anti-receptor ccr7 para o tratamento do cancro PT1904102E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
PT1904102E true PT1904102E (pt) 2010-03-29

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06776128T PT1904102E (pt) 2005-07-06 2006-07-05 Anticorpos anti-receptor ccr7 para o tratamento do cancro

Country Status (16)

Country Link
US (1) US8066996B2 (cg-RX-API-DMAC10.html)
EP (1) EP1904102B1 (cg-RX-API-DMAC10.html)
JP (1) JP5249025B2 (cg-RX-API-DMAC10.html)
KR (1) KR20080030655A (cg-RX-API-DMAC10.html)
CN (1) CN101257923A (cg-RX-API-DMAC10.html)
AT (1) ATE453407T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006265281C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0612632A2 (cg-RX-API-DMAC10.html)
CA (1) CA2614080C (cg-RX-API-DMAC10.html)
DE (1) DE602006011466D1 (cg-RX-API-DMAC10.html)
DK (1) DK1904102T3 (cg-RX-API-DMAC10.html)
ES (1) ES2338919T3 (cg-RX-API-DMAC10.html)
IL (1) IL188594A (cg-RX-API-DMAC10.html)
PT (1) PT1904102E (cg-RX-API-DMAC10.html)
RU (1) RU2404808C2 (cg-RX-API-DMAC10.html)
WO (2) WO2007003216A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
WO2009139853A2 (en) * 2008-05-14 2009-11-19 Kim, Eldar Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
JP5801202B2 (ja) * 2009-09-29 2015-10-28 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
JP5315495B2 (ja) * 2010-09-28 2013-10-16 積水化学工業株式会社 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
WO2015147335A1 (ja) * 2014-03-27 2015-10-01 国立大学法人大阪大学 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
KR102663440B1 (ko) * 2015-08-10 2024-05-07 펩맵 비.브이. 인간화된 항-ccr7 리셉터 항체
JP2018530560A (ja) 2015-10-09 2018-10-18 サレプタ セラピューティクス， インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
JP2022514867A (ja) * 2018-12-18 2022-02-16 カタパルト セラピューティクス ビー．ヴイ． 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
ATE382372T1 (de) * 2003-06-11 2008-01-15 Univ Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten

Also Published As

Publication number Publication date
IL188594A (en) 2012-02-29
CN101257923A (zh) 2008-09-03
AU2006265281B2 (en) 2012-03-01
BRPI0612632A2 (pt) 2012-01-03
EP1904102B1 (en) 2009-12-30
DK1904102T3 (da) 2010-04-19
ATE453407T1 (de) 2010-01-15
CA2614080A1 (en) 2007-01-11
US8066996B2 (en) 2011-11-29
WO2007003426A1 (en) 2007-01-11
AU2006265281A1 (en) 2007-01-11
JP2008545000A (ja) 2008-12-11
WO2007003216A1 (en) 2007-01-11
US20090123483A1 (en) 2009-05-14
IL188594A0 (en) 2008-04-13
CA2614080C (en) 2014-08-26
EP1904102A1 (en) 2008-04-02
AU2006265281C1 (en) 2012-11-15
KR20080030655A (ko) 2008-04-04
RU2008104420A (ru) 2009-08-20
JP5249025B2 (ja) 2013-07-31
DE602006011466D1 (de) 2010-02-11
ES2338919T3 (es) 2010-05-13
RU2404808C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
ES2550621T3 (es) Anticuerpos anti-CD19 y usos en oncología
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
KR101818741B1 (ko) 암 치료용 모노클로날 항체
AU2002236519A1 (en) Methods for the prevention and treatment of cancer using anti-C3B(i) antibodies
US20160257756A1 (en) Antibodies against ccr9 and applications thereof
CN102827287A (zh) 用于诊断和治疗癌症的组合物和方法
CN110997724A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
CN101547936A (zh) 癌性疾病调节抗体
CN101553259A (zh) 显示cd63表面表达的细胞的细胞毒性介导
KR20160101196A (ko) 암의 치료 및 예방을 위한 clptm1l 표적화
CN110386981A (zh) 抗gitr抗体及其用途
CA3130113A1 (en) Antibodies to cell adhesion molecule-related/down-regulated by oncogenes (cdon) and uses thereof
US12622976B2 (en) Targeting CLPTM1L for treatment and prevention of cancer
AU2001234925A1 (en) Methods for the prevention and treatment of infections using anti-C3b(i) antibodies
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
WO2023212632A2 (en) Anti-nucleophosmin 1 antibody and antibody conjugate combination therapies
EP4514858A2 (en) Mutant and mislocalized cell surface nucleophosmin 1 as a diagnostic and therapeutic target of human disease
BRPI0901452A2 (pt) métodos para o tratamento de leucemia mielóide aguda